Explore the groundbreaking PROMISE-US study on ibalizumab, a monoclonal antibody offering new hope for patients with multidrug-resistant HIV.
Exploring ibalizumab's breakthrough in treating multidrug-resistant HIV across disease severity levels through the TMB-311 expanded access trial.